The binding of iodinated botulinum toxin type B to nerve membranes was studied by using rat and mouse preparations. The toxin was examined both in the single-chain and in the proteolytically processed dichain form, and binding sites both in the spinal cord and in various brain regions were assayed. Rat and mouse brains possessed specific binding sites for botulinum toxin type B. The average K d values for the various rat and mouse membrane preparations examined were 4.2 ؎ 0.7 nM and 3.7 ؎ 0.9 nM, respectively. The average B max values for the same tissue preparations were 7.3 ؎ 0.7 pmol/mg of protein and 7.5 ؎ 1.9 pmol/mg protein, respectively. The binding of botulinum toxin type B to rat brain membranes was not antagonized by a polyclonal antibody against the cytosolic domain of synaptotagmin 1 or by a monoclonal antibody directed against the luminal domain of synaptotagmin 1. In addition, these antibodies did not protect the mouse phrenic nervehemidiaphragm from toxin-induced neuromuscular blockade. Extraction of whole-brain mRNA and injection into Xenopus oocytes led to expression of binding sites for botulinum toxin. Extraction and injection of cerebellar mRNA led to expression of a higher density of binding sites. The number of binding sites was not diminished when oocytes were pretreated with antibodies against the cytosolic and luminal domains of synaptotagmin 1. These findings are likely to aid in the isolation, characterization, and reconstitution of toxin binding sites.
Botulinum toxin is a large protein synthesized and released by the organisms Clostridium botulinum, Clostridium baratii, and Clostridium butyricum. The toxin exists in seven different serotypes, designated A through G, but each of these serotypes has a similar structure and mechanism of action (for a review of the toxin structure, see reference 10). In the immediate posttransitional stage, botulinum toxin is a single-chain polypeptide with a molecular weight of ca. 150,000. Some organisms possess an endogenous protease that cleaves the toxin to yield a dichain molecule (molecular weights of heavy and light chains, ca. 100,000 and ca. 50,000, respectively) with an interchain disulfide bond. In the absence of endogenous protease, the toxin can be cleaved by exogenous proteases such as trypsin. Proteolytic processing is essential for the toxin to attain full biological activity.
All serotypes of botulinum toxin act preferentially on cholinergic nerve endings to block acetylcholine release (for reviews of the mechanism of toxin action, see references 12, 29, and 30). The toxin produces this effect by proceeding through an elaborate series of steps, the first of which involves toxin binding to receptors on the surface of nerve membranes. The identity of these receptors and their role in cell structure or function have not been determined. The next step in the sequence is productive internalization, which in reality is a combination of two events. The toxin penetrates the cell membrane by receptor-mediated endocytosis, and it then penetrates the endosome membrane by pH-induced translocation. Toxin that reaches the cytosol acts enzymatically to cleave synaptobrevin (24-26, 28, 34, 35) , SNAP-25 (3, 6, 27) , or syntaxin (7) , which are polypeptides that are essential for docking and fusion of vesicles. Cleavage of these polypeptides culminates in the blockade of exocytosis.
Of the various steps involved in the toxin-induced blockade of transmitter release, the intracellular poisoning step is the one that has been most well characterized. At least a portion of the catalytic domain of each serotype has been determined, the substrate or substrates for each serotype have been identified, and the cleavage sites within the substrates have been localized (3, 6, 7, 24-26, 28, 34, 35) . Neither the binding step nor the internalization step has been so carefully analyzed. In relation to research on toxin binding, work has progressed through two distinct phases. During the initial phase, various laboratories performed kinetic analyses of toxin association and dissociation with brain membrane preparations. Thus, K d values and B max values for several serotypes have been reported (for reviews, see references 15 and 17) . More recently, attempts have been made to isolate and characterize toxin receptors. Although in the main this research has not been successful, there may be one exception. In a series of papers, Nishiki et al. have published evidence that synaptotagmin may constitute a portion of the binding site for serotype B (19) (20) (21) .
In the present work, a novel approach has been used to study toxin interaction with biological membranes. mRNA of mammalian brain origin was injected into Xenopus oocytes in an attempt to induce expression of toxin binding sites. This was accomplished by proceeding through three steps. First, botulinum toxin was purified to essential homogeneity and radiolabeled to high specific activity. Next, toxin binding in various regions of mouse and rat brains was quantified. Finally, mRNA extracted from tissues with the highest density of toxin binding sites was injected into oocytes and the appearance of novel binding sites was monitored. This strategy may help to clarify the identity of botulinum toxin receptors and the role of these molecules in cell function.
MATERIALS AND METHODS
Botulinum toxin. Botulinum toxin type B was isolated and purified as previously described (23, 32) . The toxin was extracted from young cultures that were free of proteases that nick the molecule, and thus the toxin was isolated in the single chain form. Conversion of the toxin to the dichain form was achieved by adding it to N-tosyl-phenylalanine chloromethylketone-treated trypsin that was coupled to agarose beads (trypsin/toxin ratio, 1:40 [wt/wt]). The mixture was incubated at 37°C for 15 min in 0.02 M sodium phosphate buffer, pH 7.0. The reaction was terminated by centrifugation and later aspiration of activated toxin. The homogeneity and molecular structure of the toxin were confirmed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. The biological activity of the nonactivated and activated species of the toxin was assayed on phrenic nerve-hemidiaphragm preparations (see below).
Botulinum toxin type B was radioiodinated with the Bolton-Hunter reagent. Purified toxin (100 g) was mixed with 1 mCi of 125 I-labeled Bolton-Hunter reagent in 100 mM borate buffer, pH 8.0, for 30 min at room temperature. Iodinated toxin was separated from free iodine by fractionation of the reaction mixture on a Sephadex G-50 column. Various preparations of the labeled material had a specific activity of 600 to 900 Ci/mmol and a residual toxicity of 70 to 90%.
Synaptotagmin antibodies. A monoclonal antibody directed against the luminal domain of synaptotagmin 1 was kindly provided by Pietro de Camilli (Boyer Center for Molecular Medicine and Howard Hughes Medical Institute, Yale University). This antibody was generated against rabbit antigen, but in preliminary experiments it was shown to cross-react with mouse and rat synaptotagmin (28a) . A polyclonal antibody against the cytosolic domain of synaptotagmin 1 was kindly provided by Troy Littleton (Division of Neuroscience and Howard Hughes Medical Institute, Baylor University). This antigen was raised against a drosophila antigen, but it too showed cross-reaction with mouse and rat synaptotagmin (28a).
Neuromuscular preparations. Mouse phrenic nerve-hemidiaphragm preparations were excised and used as previously described (9 When tissues were used to bioassay the activity of toxin preparations, tissues were immediately immersed in medium at 35°C. Various concentrations of toxin were added (see Results), after which phrenic nerves were stimulated (0.5 Hz) and the amount of time necessary for development of paralysis was monitored. When tissues were used to detect any possible interaction between antagonists and toxin, they were immersed in medium at 5°C. The putative antagonist was added for 30 min, after which toxin was added for an additional 30 min (in the continuing presence of antagonist). At the end of the 60-min incubation period, tissues were washed and suspended in antagonist-free, toxin-free solution at 35°C, and paralysis was monitored as described above. Neuromuscular blockade was defined as a 90% reduction in muscle twitch evoked by nerve stimulation.
Nerve membrane preparations. Brains and spinal cords were obtained from mice and rats. Tissues were removed according to protocols approved by the Jefferson Medical College Institutional Animal Care and Use Committee.
Nerve membrane preparations were obtained by homogenizing brain or spinal cord in iced Tris-HCl buffer (50 mM, pH 7.4). The homogenate was centrifuged for 10 min at 1,000 ϫ g, and the resulting supernatant was recentrifuged for 45 min at 40,000 ϫ g. The final pellet was resuspended in Tris-HCl buffer (as above).
Ligand binding experiments. The binding of iodinated botulinum toxin type B to nerve membrane preparations was measured by a centrifugation assay as previously described (1, 2) . The ligand was mixed with a specified concentration of membrane (see Results) in 100 l of buffer containing 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, and bovine serum albumin (1 mg/ml). The binding reaction was allowed to proceed at room temperature (ca. 23°C) for the amount of time necessary to reach equilibrium (see Results). The reaction was terminated by centrifugation (15,000 ϫ g, 2 min), after which the pellet was washed with fresh buffer and recentrifuged. Membrane-associated ligand was collected and quantified, and the results were corrected for nonspecific binding. The data were evaluated by using the equilibrium binding analysis program of McPherson (14) .
Isolation of mRNA. Total RNA was extracted and isolated by the RNAzol B (BIOTECX Laboratories, Inc., Houston, Tex.) method, essentially as described in the product literature. Brain tissue was homogenized in RNAzol B solution with a Brinkmann Polytron. The homogenate was mixed with chloroform (10% by volume) and vigorously shaken for 15 s. The suspension was centrifuged at 12,000 ϫ g for 15 min, after which the colorless aqueous phase was collected. Total RNA was precipitated by adding an equal volume of isopropanol (0°C, 30 min). Precipitated total RNA was collected and washed once with 70% ethanol. mRNA [poly(A) RNA] was separated from total RNA by the Expresep (BIO-TECX Laboratories, Inc.) method, as described in the product literature. Isolated mRNA was dissolved in diethylpyrocarbonate-treated water and stored at Ϫ80°C.
Xenopus oocytes. Oocytes were obtained from adult female Xenopus laevis (African clawed) toads. One lobe of the ovary was surgically excised from each toad (anesthetized with a 0.2% aqueous solution of 3-aminobenzoic acid ethyl ester methanesulfonate salt), and oocytes were separated by incubation in calcium-free saline (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 5 mM HEPES [pH 7.6]) containing collagenase A (2 mg/ml). Defolliculated oocytes were maintained in sterile solution (50% Leibovitz's solution containing 5 mM glutamine and 15 mM HEPES at pH 7.6, plus gentamicin [100 mg/ml]) at 18°C for at least 8 h before being used. Oocytes were then microinjected with mRNA (75 to 100 ng/oocyte) and incubated for another 2 to 3 days. Oocyte membranes were prepared similarly to brain membranes, except that the original centrifugation was at 300 ϫ g and the subsequent centrifugation was at 30,000 ϫ g.
RESULTS

Characterization of ligand.
Botulinum toxin type B isolated as previously described (32) was collected from a single peak at the conclusion of a series of chromatographic steps. Polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate confirmed that the isolated toxin was essentially homogeneous and in the single-chain form (Fig. 1) . Proteolytic processing of the toxin with agarose-bound trypsin resulted in almost complete conversion to the dichain form (Fig. 1) .
The relative potencies of the single-chain and dichain species were bioassayed on the mouse phrenic nerve-hemidiaphragm preparation, as previously described (31) . Proteolytic processing of the toxin resulted in an increase in potency of more than an order of magnitude (Fig. 2) .
Single-chain and dichain forms of the toxin were radioiodinated, as described in Materials and Methods, to give preparations with high specific activity (range, 600 to 900 Ci/mmol). Labeled material was bioassayed for residual toxicity, as described above, and was found to retain between 70 and 90% of the activity of the native toxin.
Radiolabeled toxin was subjected to polyacrylamide gel electrophoresis, and individual lanes containing the single-chain and dichain forms of the toxin were excised and cut into 2-mmwide strips. As expected, lanes containing the single-chain species had a single peak of radioactivity, and this peak migrated in a manner consistent with a molecular weight of ϳ150,000 ( Fig. 1) . Lanes containing the dichain species had two major peaks, and the molecular weights were consistent with those of the heavy chain (ϳ95,000 to 100,000) and light chain (ϳ51,000) of botulinum toxin. Interestingly, the fraction of radioactivity associated with the heavy chain (ϳ78%) was greater than that predicted on the basis of molecular weight. This means that radioactivity was enriched in that portion of the toxin molecule thought to mediate binding.
Binding of toxin to nerve membrane preparations. In an initial series of experiments, membrane preparations from rat (brains), mouse (brains), and oocyte (whole cells) were tested for their ability to bind iodinated dichain toxin. Standard conditions for this binding assay were as follows: toxin concentration, 0.5 to 1.0 nM; membrane concentration, 100 g/assay; reaction volume, 100 l; time, 2 h; and temperature, 23°C. These conditions were similar to those previously used to study clostridial toxin binding to brain membrane preparations (1, 2) .
These preliminary experiments indicated that tissues of rat and mouse origin displayed binding sites for toxin. Kinetic analyses and regional binding data are presented below. In contrast, native oocyte membranes had no specific binding sites for toxin. This suggests that oocytes could be an acceptable system in which to induce expression of binding sites.
Characteristics of toxin binding to rat brain and spinal cord membranes. Botulinum toxin type B binding to rat membrane preparations increased as a function of protein (Fig. 3A ). An apparent plateau was observed in the range of 20 to 30 g of membrane protein per assay (reaction volume, 100 l). This result was obtained both with brain and with spinal cord preparations. All subsequent experiments were done at a membrane protein concentration of 15 g per assay.
The binding of botulinum toxin to membrane preparations increased with time, and a true equilibrium was not reached until 60 to 90 min (Fig. 3B ). This incubation time was incorporated into subsequent experiments.
Temperature had a significant effect on specific binding. The greatest amount of specific binding was obtained at 23°C. This binding was reduced at 37°C, and it was markedly reduced at 0°C (Fig. 3C ). All subsequent experiments were done at room temperature (ϳ23°C). Specific binding of the single-chain and dichain species of botulinum toxin type B were compared, using the assay conditions described in the preceding paragraphs. Regardless of the origin of tissues, the two species were indistinguishable in their binding characteristics (not illustrated). All subsequent experiments were done with the single-chain molecule.
Various concentrations of iodinated botulinum toxin type B were incubated with rat brain membrane preparations, and the resulting data on specific binding were used to generate a saturation isotherm and a Scatchard plot (Fig. 4) . Graphic analysis of the data revealed a single class of binding sites with a K d of 2 nM and a B max of 2.6 pmol/mg of protein. In companion experiments, various concentrations of unlabeled toxin were used as competitive antagonists of labeled toxin binding (Fig. 5) . The apparent 50% inhibitory concentration (IC 50 ) as deduced by graphic analysis was 2 nM, which is in accord with the K d for radioligand binding (see above).
Unlike homologous toxin, heterologous unlabeled toxin was not an effective antagonist of iodinated botulinum toxin type B binding. At concentrations 10-fold greater than the IC 50 for unlabeled serotype B, unlabeled serotypes A and C produced less than 20% inhibition of iodinated toxin binding (results not illustrated).
In addition to studies on membrane preparations derived from rat whole brain, work was done on preparations from select regions, including the forebrain, basal forebrain, cerebellum, and spinal cord ( Table 1 The data indicated that the average binding affinity for these four regions was slightly less than that for whole brain (i.e., higher K d value; see above), but the average density of binding sites was slightly higher. Botulinum toxin binding to mouse membrane preparations. A more limited series of studies was done on membrane preparations from different regions of mouse brain. Representative data for one specific region (saturation isotherm and resulting Scatchard analysis) showed that mouse basal forebrain had a single class of high-affinity binding sites for iodinated botulinum toxin (Fig. 6 ). The K d was 4.1 nM and the B max was 8.4 pmol/mg of protein, which are reasonably similar to the values for whole rat brain preparations.
When three specific tissues (cerebellum, forebrain, and basal brain) were analyzed, the resulting K d values fell within a narrow range (2.9 ϫ 10 Ϫ9 to 4.3 ϫ 10 Ϫ9 M), and this range fell within that observed for rat tissues (Table 1) . On the other hand, the resulting B max values were more disparate. The difference between the values for the mouse cerebellum (12 pmol/mg of protein) and the mouse forebrain (2 pmol/mg of protein) was sixfold. The relatively high value obtained in mouse cerebellar membranes was exploited in expression experiments.
Expression of binding sites in oocytes. The binding of botulinum toxin to Xenopus oocytes was examined before or after injection of mRNA (see Materials and Methods). A single toxin concentration was used (10 Ϫ9 M), and conditions for the 3 g ) was added to both lanes. The single-chain and dichain forms of the toxin were subjected to two additional procedures. The single-chain and dichain molecules were radiolabeled with Bolton-Hunter reagent as described in the text and then run on reducing gels as indicated above. The gels were cut into 2-mm-wide sections, and the amount of radioactivity was quantified. The results demonstrated that radioactivity of the single-chain preparation (F) migrated in accordance with the known molecular weight of the holotoxin (ca. 150,000) and that the radioactivity of the dichain preparation (ϫ) migrated in accordance with the molecular weights of the heavy chain and light chain (ca. 100,000 and 51,000). The two forms of botulinum neurotoxin type B were also bioassayed for activity. The results are illustrated in Fig. 2 . binding assay were identical to those used with rat brain tissues (see above).
As described earlier, membranes from native oocytes were devoid of specific binding sites. However, in most cases (Ͼ80%), injection of message from whole rat brain led to expression of specific binding sites. The average value obtained for membranes in nine successful experiments was 30 Ϯ 4 fmol/mg of protein.
Earlier experiments on rat and mouse brain demonstrated that the cerebellum had the highest density of toxin binding sites. Therefore, mRNA from rat cerebellum or mouse cerebellum was injected into oocytes. Interestingly, the success rate in obtaining binding sites rose to 100% when cerebellar mRNA was injected. The actual values obtained were as follows: rat cerebellum mRNA, 40 Ϯ 5 fmol/mg of protein (n ϭ 4); mouse cerebellum mRNA, 42 Ϯ 10 fmol/mg of protein (n ϭ 4).
The effects of synaptotagmin antibodies on botulinum toxin binding and activity. Rat brain membrane preparations were incubated (30 min; 23°C) with antibody against either the cytosolic or luminal domains of synaptotagmin 1. The antibodies were used at a fivefold excess to the concentration which has been shown to bind to and label epitopes on synaptic vesicles (18) . Iodinated botulinum toxin type B was then added (10 Ϫ9 M), and binding was measured as described above. The results indicated that neither antibody reduced the amount of toxin binding (not illustrated).
In related experiments, phrenic nerve-hemidiaphragm preparations were immersed in medium at 5°C, which virtually abolishes both exocytosis and endocytosis. Antibody against either the cytosolic or luminal domain of synaptotagmin was added, and incubation was continued for 30 min. Botulinum toxin type B (10 Ϫ11 M) was then added, and incubation was continued for an additional 30 min. Tissues were washed and suspended in antibody-free and toxin-free solution at 35°C, phrenic nerves were stimulated, and paralysis times were monitored. The results were as follows: control tissues (n ϭ 10), 111 Ϯ 9 min; tissues incubated with antibody against the cytosolic domain of synaptotagmin (n ϭ 4), 118 Ϯ 12 min; and tissues incubated with antibody against the luminal domain of FIG. 2. The single-chain (E) and dichain (ᮀ) forms of botulinum neurotoxin were assayed for activity on the mouse phrenic nerve-hemidiaphragm preparation. Nerves were stimulated at a rate of 1.0 Hz. Paralysis time was defined as the amount of time necessary for toxin to produce a 90% reduction in nerve stimulus-evoked muscle responses. Each data point represents the mean Ϯ standard error of the mean (error bar) of four or more nerve preparations. Note that proteolysis of the toxin was associated with a shift in the concentration-response curve of more than an order of magnitude. a The binding of iodinated toxin to membrane preparations was examined under the following conditions: membrane protein concentration, 15 g per assay; incubation time, 60 to 90 min; and incubation temperature, 23°C. Specific binding was quantified by subtracting nonspecific binding (e.g., iodinated toxin in the presence of a 50-fold molar excess of unlabeled toxin) from total binding (e.g., iodinated toxin alone). Values are expressed as means Ϯ standard errors of the means. For each group, n is Ն3. domain of synaptotagmin, and experimental preparations preincubated with antibody against the luminal domain of the peptide were compared. Preincubation with each antibody was for 30 min at 23°C. The results demonstrated that the amount of specific binding in the three tissue preparations was the same. There was no evidence for antagonism of toxin binding by either antibody.
DISCUSSION
Botulinum toxin acts preferentially on cholinergic nerve endings to block acetylcholine release. The toxin produces this effect by proceeding through a sequence of events, the first of which is association with cell surface receptors. The identity of these receptors and their role in nerve function have not been determined (15) . Indeed, it has not even been established whether there are simple receptors. Montecucco (16) has advanced the interesting idea that binding might be a biphasic process. There could be an initial interaction with lower-affinity binding sites (viz., membrane lipids), and this would promote a secondary interaction with higher-affinity sites (viz., protein). The value of this proposal and others will not be known until toxin receptors are actually identified.
A strategy for characterizing receptors. A number of investigators have studied labeled botulinum toxin binding to nerve membrane preparations (for representative studies, see references 11, 13, 33, and 36). Because the amount of nerve ending tissue at the neuromuscular junction is limited, almost the entire literature on binding deals with brain membrane preparations (but see the works by Black and Dolly [4, 5] ). This is in keeping with the fact that botulinum toxin blocks transmitter release from isolated brain synaptosomes.
Earlier studies on botulinum toxin type B binding have shown that whole-brain preparations have specific, high-affinity binding sites (11, 13) . Furthermore, these binding sites are unique or relatively unique to this serotype, because heterologous serotypes do not block binding. These earlier studies have established a framework in which the present work was done.
Botulinum toxin type B was labeled to high specific activity, and its binding was studied in several discrete areas of the rat and mouse central nervous systems. An initial examination of iodinated type B toxin binding showed that the single-chain and dichain species were virtually indistinguishable. This is in marked contrast to findings with other steps in the paralytic process. To begin with, the single-chain species does not appear to have the correct conformation and/or flexibility needed for cellular internalization. In addition, the single-chain species expresses little or no enzymatic activity, perhaps because of conformational restraints on the catalytic domain. These limitations explain why the single-chain molecule is much less potent than the dichain molecule when tested on phrenic nerve-hemidiaphragm preparations.
The membrane preparations used in the present study did not have intact synaptosomes, and thus there should have been little possibility that the process of internalization could be mistaken for binding. However, to minimize any difficulties, the bulk of the work was done with the single-chain molecule. This also reduced the prospect that toxin-substrate interactions could complicate matters, because, as indicated above, the single-chain molecule has little enzymatic activity.
Analysis of toxin binding. All regions of rat and mouse central nervous systems that were tested had specific binding sites for botulinum toxin type B. In general, the K d values for the different regions of rat and mouse brain were comparable.
There is one important point that should be made in relation to the binding data. Previous work has shown that botulinum toxin type B is orders of magnitude more potent in blocking mouse neuromuscular transmission than in blocking rat neuromuscular transmission (8) . To the extent that binding to brain membranes reflects binding to motor nerve membranes, the data suggest that resistance of the rat is not due to an absence of specific receptors (see the work of Evans et al. [11] ). This conclusion meshes well with another line of recent research. Botulinum toxin type B blocks transmission by cleaving synaptobrevin (also known as VAMP, or vesicle-associated membrane protein) at Gln76-Phe77. Mouse synaptobrevin has this bond, but rat synaptobrevin has a substitution at this site that creates a Val76-Phe77 bond (22) . In all likelihood, resistance of the rat to serotype B is due to an absence of a susceptible cleavage site in the substrate and not to absence of specific receptors.
In contrast to brain and spinal cord, native Xenopus oocytes were devoid of specific binding sites for botulinum toxin type B. However, injection of oocytes with mRNA of whole rat brain origin led to expression of binding sites, and injection of mRNA of either rat cerebellum or mouse cerebellum origin led to expression of even more binding sites. These results are encouraging, not only because they demonstrate that binding sites can be induced in oocytes but also because they demonstrate that the relative density of binding sites in the expression system mimics the relative density in the donor tissue.
Putative role of synaptotagmin. In the recent past, Nishiki et al. (19, 20) have published works suggesting that synaptotagmin, perhaps in association with another molecule, may act as a receptor for serotype B. Synaptotagmin is enriched in the membranes of synaptic vesicles. During the process of transmitter release, synaptic vesicles fuse and then meld with the plasma membrane. This means that for a finite period of time the luminal domain of synaptotagmin is exposed to the cell surface. It is at this point that, hypothetically, synaptotagmin could serve as a whole or partial receptor for the toxin. Therefore, botulinum toxin binding and biological activity were studied in the absence and presence of antibodies against synaptotagmin.
Experiments in which antibodies against the luminal and cytosolic domains of synaptotagmin 1 were tested as antagonists of toxin binding to brain membrane preparations did not reveal any protection. The antibodies, like the toxin, are large molecules (Ͼ150,000 Da), which means that antibodies could block toxin binding either by attaching to the toxin binding site (viz., true competition) or by attaching to an adjacent site (viz., steric hindrance). The finding that there was a complete absence of protection suggests that synaptotagmin 1 is not acting as a sole receptor.
The binding studies on brain membrane preparations were supplemented by experiments on oocytes and on phrenic nerve-hemidiaphragm preparations. Native oocytes did not express specific receptors for toxin, but injection of rat or mouse cerebellar mRNA did lead to expression of binding sites. In keeping with the results for brain membranes, antibodies against the two free domains of synaptotagmin 1 did not diminish toxin binding to oocyte membranes. Analogous results were obtained in functional studies with a neuromuscular preparation. Antibodies against synaptotagmin 1 did not alter the amount of time necessary for toxin-induced blockade of transmission in the phrenic nerve-hemidiaphragm.
The neuromuscular junction studies are especially relevant to issues that pertain to toxin binding. As discussed above, it is presumably the luminal domain of synaptotagmin that would serve as a binding site, and this portion of the molecule would be exposed when exocytotic vesicles meld with the plasma membrane. The number of these binding sites would be low under conditions in which there is little or no exocytosis (e.g., low temperature), but the relative number and rate of turnover would increase when there is substantial exocytosis (e.g., rapid nerve stimulation). Indeed, recent work has demonstrated exactly this outcome. Mundigl and colleagues (18) have shown that an iodinated antibody against the luminal domain of synaptotagmin 1 can be used to measure exocytosis. This work has shown that binding is reduced at low temperatures, but binding of the antibody increases at physiological temperatures or with nerve depolarization.
Experiments in the present study involved the same antibody as that developed to measure exocytotic activity. The antibody was added to the neuromuscular junction at 4°C for 30 min, which is more than adequate time for equilibrium to be obtained (ca. 3 to 4 min [18] ). Botulinum toxin was then added for 30 min, after which tissues were washed and suspended in physiological solution at 35°C. The results demonstrated that prior treatment of tissues with antibodies against synaptotagmin 1 did not afford any protection against botulinum toxin type B.
The combined results raise questions about the role of synaptotagmin 1 as a sole receptor for botulinum toxin. However, they do not necessarily challenge the premise that the peptide could be one part of a dual receptor. The absence of antibody protection in binding experiments could be explained on the basis that toxin was associating with the nonsynaptotagmin portion of the dual receptor. The absence of protection in functional experiments could be explained on the same basis, with the assumption that the toxin becomes associated with newly exposed synaptotagmin when nerve stimulation begins.
Another and perhaps more important point is that synaptotagmin 1 is only the first in what is now a growing family of synaptotagmins. It is possible that another of the several forms of synaptotagmin is the full or partial receptor for serotype B. Indeed, this concept is strengthened by a report that appeared while the present work was in progress. Nishiki et al. (21) have found that botulinum toxin has a greater affinity for synaptotagmin 2 than synaptotagmin 1. This finding suggests that serotype B should be examined for its ability to bind to all members of the synaptotagmin family. The resulting data on affinity constants could be used as a basis for deciding which synaptotagmin to express in oocytes in an effort to reconstitute botulinum toxin binding sites.
